Background Hidradenitis suppurativa (HS) is a chronic inflammatory condition primarily affecting pilosebaceous units in areas with apocrine sweat glands. Although treatment options vary, intralesional therapies are often necessary, even under systemic treatment, but have limitations […]
Background and objective Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Treatment for moderate-to-severe HS includes biologic therapies (adalimumab and secukinumab), resulting in increased disease management costs. Our aim was to estimate the difference […]
Background and objective Hidradenitis suppurativa (HS) is a chronic, progressive inflammatory disease with a substantial impact on quality of life. Accessibility to specialized units and referral methods may significantly influence clinical characteristics and therapeutic decisions. […]
Background Bimekizumab is the first and only dual selective inhibitor of IL-17 A and IL-17 F that has been proven effective and safe in Phase 3 clinical trials and has been approved by the European […]
Background and objectives Plaque psoriasis (Pso) and hidradenitis suppurativa (HS) are chronic inflammatory diseases associated with multiple comorbidities, including cardiovascular conditions, which may negatively impact survival. The aim of this study was to analyze mortality […]
Background and objectives Evidence for secukinumab and bimekizumab in hidradenitis suppurativa (HS) primarily comes from randomized clinical trials with selected patient populations. Conversely, real-world evidence (RWE) studies reflect broader patient demographics and clinical practice. This […]
Introduction Hidradenitis suppurativa (HS) is a skin disease that significantly impacts patients’ quality of life. There are still uncertainties surrounding its epidemiology, natural history, and the safety and effectiveness of existing treatments. The Spanish Academy […]
Although comedones are a prevalent entity in multiple skin diseases, their perianal location as a cluster is a rare finding. We describe 5 patients with grouped perianal comedones who developed the lesions in adulthood and […]
It is necessary to identify which factors or comorbidities are associated with more severe hidradenitis suppurativa, aiming to identify which patients may benefit more from early systemic treatment or a more aggressive approach. A retrospective […]
Background and objective Topical and intralesional (IL) treatments may be considered the first-line therapy in patients with hidradenitis suppurativa (HS); however, the evidence supporting their use is limited. The aim of our review is to […]